Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Amazon investiert Millionen in Kernenergie - so können Sie sich früh positionieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1T65B | ISIN: US16934W1062 | Ticker-Symbol: CXF
Tradegate
23.01.25
18:51 Uhr
3,775 Euro
+0,150
+4,14 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CHIMERIX INC Chart 1 Jahr
5-Tage-Chart
CHIMERIX INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,7003,75519:00
3,7003,75519:00

Aktuelle News zur CHIMERIX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiChimerix-Aktie erreicht 52-Wochen-Hoch bei 3,8 US-Dollar5
DiChimerix stock soars to 52-week high, hits $3.82
13.01.Here's Why Chimerix, Inc. (CMRX) Is Skyrocketing7
30.12.24A Glimpse Into The Expert Outlook On Chimerix Through 4 Analysts18
CHIMERIX Aktie jetzt für 0€ handeln
30.12.24Chimerix Announces NDA Submission For Dordaviprone6
30.12.24Chimerix, Inc.: Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma180DURHAM, N.C., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients...
► Artikel lesen
30.12.24CHIMERIX INC - 8-K, Current Report-
27.12.24Chimerix stock soars to 52-week high, hits $3.443
27.12.24Chimerix-Aktie erreicht 52-Wochen-Hoch bei 3,44 US-Dollar11
10.12.24Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday?36
10.12.24Chimerix soars on seeking accelerated approval for its glioma treatment to U.S. FDA41
10.12.24CHIMERIX INC - 8-K, Current Report9
09.12.24Chimerix, Inc.: Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End158Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on Tuesday...
► Artikel lesen
06.12.24Chimerix, Inc.: Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)240DURHAM, N.C., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on December 2, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards...
► Artikel lesen
11.11.24Chimerix, Inc.: Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting210DURHAM, N.C., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients...
► Artikel lesen
07.11.24CHIMERIX INC - 10-Q, Quarterly Report6
07.11.24CHIMERIX INC - 8-K, Current Report1
01.11.24Chimerix, Inc.: Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 202420
18.10.24Chimerix, Inc.: Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)129DURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on October 16, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement...
► Artikel lesen
30.08.24Chimerix, Inc.: Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)221DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement award...
► Artikel lesen
Seite:  Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1